Europe Antibody Drug Conjugates Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Target (CD 30, CD 22, HER 2), By Indication (Haematologic, Non-Haematologic Malignancies), And By Country - Forecast From 2022 To 2027

Published:  May 2022 Report Code: KSI061613004 Pages: 84

The European antibody-drug conjugate (ADCs) market is expected to grow at a CAGR of 22.37% to reach a market size of US$4.467 billion by the end of 2027, up from US$1.087 billion in 2020.

Major factors that are contributing to the growth of the market include the rising prevalence of cancer across European countries, the increasing geriatric population, and rising investments in research and development activities to develop novel therapeutic drugs. Antibody-drug conjugates are anticancer drugs that provide one of the fastest-growing treatments for cancer patients. ADCs use antibodies to deliver high potential cytotoxic drug molecules to the targeted tumour-related antigens for cancer treatment. Some of the recent advancements that have been made in ADC technology are- the approval of 10 ADCs, including Adcetris and Kadcyla, which are specific for Cd30 and HER2 antigen sites, respectively.

 Europe Antibody Drug Conjugates Market Drivers

  • The  rising prevalence of cancer

One of the prime reasons supporting the growth of the European antibody-drug conjugate market is the rising prevalence of cancer across various countries in Europe. With more than 3.7 million new cases and 1.9 million deaths every year, cancer represents the second most important cause of death and morbidity in Europe. The region comprises one-eighth of the total world population but has approximately one-quarter of the global total of cancer cases, with more than 3 million patients per year. Female breast cancer is one of the most commonly diagnosed cancers in Europe. Over 355,000 women in the EU-27 are estimated to be diagnosed with breast cancer in 2020. Based on these statistics it can be said that there will be a huge demand for ADC for the treatment of cancer patients across various countries in Europe. ADC shows promising results for heavily pretreated diseases such as CNS metastases, as well as a targeted approach for treating CD30 and HER2 positive breast cancer.  Moreover, the increasing research and development activities for the treatment of breast cancer and the improvement of survival rates are further projected to drive the market growth across the region. Several companies in the region are working on the development of highly potent ADCs for the cure of haematological and non-haematological malignancies.

Antibody Drug Conjugates Market in Europe by Country  

  • Germany and France are expected to dominate the market growth during the forecast period:

Among all the European countries, Germany and France are expected to dominate the market growth due to the high healthcare expenditure, which provides an opportunity for the companies operating in the market to grow and launch more innovative products. The total healthcare expenditure in Germany was around EUR 403 billion in 2019, which is estimated to be the highest among all the EU countries (Source: Eurostat). France stands in the second position after Germany, followed by Italy and Spain. Additionally, increased government schemes that financed 28.2% of the overall healthcare expenditure in Europe in 2019, and increased spending by EU member states on preventive health care are projected to support the overall market growth. According to Eurostat, member states of Europe spent €39.6 billion on preventive health care in 2019. Germany's healthcare market is estimated to be at the number one position in Europe by market volume, medical technology, number of patients, and healthcare providers. The country is also known as the "Pharmacy of the World," and it is the third-largest pharmaceutical market in the world and the largest in Europe. The pharmaceutical market in Germany has seen massive growth in the last few years, and the growth was driven especially by cancer drugs and anti-infective agents.                    

Covid-19 Insights

The outbreak of the COVID-19 pandemic showed a strong impact on the European antibody-drug conjugate market because, during the pandemic, all the activities within hospitals and healthcare services were halted because of the lockdown and social distancing rules or restrictions imposed by the European government. The pandemic has severely affected the economies of all European countries, which has had a huge impact on the operations and activities of general hospitals for non-COVID-19 patients and the supply chain of ADCs across the European region.

Europe Antibody Drug Conjugates Market Scope:

Report Metric Details
 Market size value in 2020  US$1.087 billion
 Market size value in 2027  US$4.467 billion
 Growth Rate  CAGR of 22.37% from 2020 to 2027
 Base year  2020
 Forecast period  2022–2027
 Forecast Unit (Value)  USD Billion
 Segments covered  Target, Indication, And Country
  Regions covered  United Kingdom, Germany, France, Others
 Companies covered Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Pfizer Inc., Synthon Holding B.V., Immunomedics GmbH, Biotest AG, Astellas Pharma Inc., Seattle Genetics, Inc.
 Customization scope  Free report customization with purchase


Market Segmentation

  • By Target
    • CD 30
    • CD 22
    • HER 2
  • By Indication
    • Haematologic Malignancies
    • Non-Haematologic Malignancies
  • By Country
    • United Kingdom
    • Germany
    • France
    • Others
1.1. Market Overview
1.2. Covid-19 Scenario
1.3. Market Definition
1.4. Market Segmentation

2.1. Research Data
2.2. Assumptions

3.1. Research Highlights

4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Powers of Buyers
4.3.3. Threat of Substitutes
4.3.4. The Threat of New Entrants
4.3.5. Competitive Rivalry in Industry
4.4. Industry Value Chain Analysis

5.1. CD 30
5.2. CD 22
5.3. HER 2

6.1. Haematologic Malignancies
6.2. Non-Haematologic Malignancies

7.1. Germany
7.2. France
7.3. UK
7.4. Others

8.1. Vendor Matrix and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players

9.1. Takeda Pharmaceutical Company Limited
9.2. F. Hoffmann-La Roche Ltd.
9.3. Pfizer Inc.
9.4. Synthon Holding B.V.
9.5. Immunomedics GmbH
9.6. Biotest AG
9.7. Astellas Pharma Inc.
9.8. Seattle Genetics, Inc.

Takeda Pharmaceutical Company Limited

F. Hoffmann-La Roche Ltd.

Pfizer Inc.

Synthon Holding B.V.

Immunomedics GmbH

Biotest AG

Astellas Pharma Inc.

Seattle Genetics, Inc.


Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


We are in compliance with the global privacy laws.

Connect With Us